Published in N Engl J Med on May 04, 1989
New insights into the biology of the acute phase response. J Clin Immunol (1999) 2.05
Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta. J Clin Invest (1991) 1.85
Interleukin-8 in sepsis: relation to shock and inflammatory mediators. Infect Immun (1992) 1.85
Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci U S A (1992) 1.76
Elevated von Willebrand factor antigen is an early plasma predictor of acute lung injury in nonpulmonary sepsis syndrome. J Clin Invest (1990) 1.71
Cellular localization of type 1 plasminogen activator inhibitor messenger RNA and protein in murine renal tissue. Am J Pathol (1993) 1.52
Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest (1994) 1.50
Plasminogen activator inhibitor-1 (PAI-1): a key factor linking fibrinolysis and age-related subclinical and clinical conditions. Cardiovasc Ther (2010) 1.46
Activated protein C inhibits local coagulation after intrapulmonary delivery of endotoxin in humans. Am J Respir Crit Care Med (2005) 1.33
Fibrin deposition in tissues from endotoxin-treated mice correlates with decreases in the expression of urokinase-type but not tissue-type plasminogen activator. J Clin Invest (1996) 1.29
Plasminogen activator inhibitor-1 in acute hyperoxic mouse lung injury. J Clin Invest (1996) 1.25
Clinical review: sepsis and septic shock--the potential of gene arrays. Crit Care (2012) 1.25
Bacterial plasminogen receptors: in vitro evidence for a role in degradation of the mammalian extracellular matrix. Infect Immun (1995) 1.12
Fibrinolytic response to tumor necrosis factor in healthy subjects. J Exp Med (1991) 1.11
Recent acquisitions in the pathophysiology, diagnosis and treatment of disseminated intravascular coagulation. Thromb J (2006) 1.10
Administration of C1 inhibitor reduces neutrophil activation in patients with sepsis. Clin Diagn Lab Immunol (2003) 1.00
Induction of plasminogen activator inhibitor 1 gene expression in murine liver by lipopolysaccharide. Cellular localization and role of endogenous tumor necrosis factor-alpha. Am J Pathol (1997) 0.99
Experimental human endotoxemia: a model of the systemic inflammatory response syndrome? Surg Infect (Larchmt) (2012) 0.98
Aging accelerates endotoxin-induced thrombosis : increased responses of plasminogen activator inhibitor-1 and lipopolysaccharide signaling with aging. Am J Pathol (2002) 0.97
Effects of recombinant human activated protein C in human models of endotoxin administration. Proc Am Thorac Soc (2005) 0.97
4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene in children with systemic meningococcaemia. Eur J Pediatr (2005) 0.94
Hyperfibrinolysis in hepatosplenic schistosomiasis. J Clin Pathol (1996) 0.94
Alpha-2-macroglobulin functions as an inhibitor of fibrinolytic, clotting, and neutrophilic proteinases in sepsis: studies using a baboon model. Infect Immun (1993) 0.93
Endotoxin stimulates expression of the murine urokinase receptor gene in vivo. Am J Pathol (1995) 0.91
A synthetic lipopolysaccharide-binding peptide based on the neutrophil-derived protein CAP37 prevents endotoxin-induced responses in conscious rats. Infect Immun (1997) 0.90
A novel mechanism of plasmin-induced mitogenesis in fibroblasts. J Thromb Haemost (2005) 0.89
Eptifibatide-induced thrombocytopenia: with thrombosis and disseminated intravascular coagulation immediately after left main coronary artery percutaneous coronary angioplasty. Tex Heart Inst J (2012) 0.82
Human endotoxemia and human sepsis: limits to the model. Crit Care (2005) 0.81
Thromboelastometry (TEM) findings in disseminated intravascular coagulation in a pig model of endotoxinemia. Mol Med (2010) 0.80
Coagulation disorders in septic shock. Intensive Care Med (1993) 0.80
Assessment of Fibrinolysis in Sepsis Patients with Urokinase Modified Thromboelastography. PLoS One (2015) 0.80
Role of endotoxemia in cardiovascular dysfunction and lethality: virulent and nonvirulent Escherichia coli challenges in a canine model of septic shock. Infect Immun (1996) 0.80
uPA Attenuated LPS-induced Inflammatory Osteoclastogenesis through the Plasmin/PAR-1/Ca(2+)/CaMKK/AMPK Axis. Int J Biol Sci (2016) 0.79
Type 1 plasminogen activator inhibitor gene expression following partial hepatectomy. Am J Pathol (1993) 0.78
Modulating LPS signal transduction at the LPS receptor complex with synthetic Lipid A analogues. Adv Carbohydr Chem Biochem (2014) 0.77
Role of alpha-2-macroglobulin and bacterial elastase in guinea-pig pseudomonal septic shock. Int J Exp Pathol (1995) 0.77
[Mechanisms of action of recombinant human activated Protein C]. Anaesthesist (2006) 0.77
Imbalance of tissue-type plasminogen activator (t-PA) and its specific inhibitor (PAI-1) in patients with rheumatoid arthritis associated with disease activity. Clin Rheumatol (1997) 0.76
The imbalance between coagulation and fibrinolysis is related to the severity of the illness and the prognosis in sepsis. Korean J Intern Med (1999) 0.76
Plasminogen activation and endotoxin. N Engl J Med (1989) 0.75
A Review of Radiation-Induced Coagulopathy and New Findings to Support Potential Prevention Strategies and Treatments. Radiat Res (2016) 0.75
Intensive care. Postgrad Med J (1993) 0.75
A model for the interplay of inflammatory mediators in sepsis--a study in 48 patients. Intensive Care Med (1990) 0.75
[Endotoxins. Pathogenetic meaning of sepsis]. Anaesthesist (2003) 0.75
Prospective evaluation of a monoclonal antibody in diagnosis of Pneumocystis carinii pneumonia. Lancet (1986) 5.65
The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med (1989) 4.24
Profound but reversible myocardial depression in patients with septic shock. Ann Intern Med (1984) 3.81
Pregnancy loss in the antiphospholipid-antibody syndrome--a possible thrombogenic mechanism. N Engl J Med (1997) 3.07
Bacteremia due to Mycobacterium avium-intracellulare in the acquired immunodeficiency syndrome. Ann Intern Med (1983) 3.06
The cardiovascular manifestations of the hypereosinophilic syndrome. Prospective study of 26 patients, with review of the literature. Am J Med (1979) 2.86
Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock. J Exp Med (1989) 2.69
Studies on human plasma alpha 2-macroglobulin-enzyme interactions. Evidence for proteolytic modification of the subunit chain structure. J Exp Med (1973) 2.56
Tumor necrosis factor alpha and interleukin 1beta are responsible for in vitro myocardial cell depression induced by human septic shock serum. J Exp Med (1996) 2.50
Diagnosis of Pneumocystis carinii pneumonia: improved detection in sputum with use of monoclonal antibodies. N Engl J Med (1988) 2.33
A circulating myocardial depressant substance in humans with septic shock. Septic shock patients with a reduced ejection fraction have a circulating factor that depresses in vitro myocardial cell performance. J Clin Invest (1985) 2.26
Studies on human plasma C1 inactivator-enzyme interactions. I. Mechanisms of interaction with C1s, plasmin, and trypsin. J Clin Invest (1975) 2.07
Monoclonal antibodies to Pneumocystis carinii: identification of specific antigens and characterization of antigenic differences between rat and human isolates. J Infect Dis (1989) 2.04
Detection of Pneumocystis carinii by fluorescent-antibody stain using a combination of three monoclonal antibodies. J Clin Microbiol (1987) 1.90
Serial cardiovascular variables in survivors and nonsurvivors of human septic shock: heart rate as an early predictor of prognosis. Crit Care Med (1987) 1.89
The diagnosis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome using subsegmental bronchoalveolar lavage. Am Rev Respir Dis (1984) 1.88
Binding of plasminogen to cultured human endothelial cells. J Biol Chem (1986) 1.87
Role of endotoxemia in cardiovascular dysfunction and mortality. Escherichia coli and Staphylococcus aureus challenges in a canine model of human septic shock. J Clin Invest (1989) 1.87
Kaposi's sarcoma causing pulmonary infiltrates and respiratory failure in the acquired immunodeficiency syndrome. Ann Intern Med (1985) 1.86
The coronary circulation in human septic shock. Circulation (1986) 1.83
Takayasu's arteritis and its therapy. Ann Intern Med (1985) 1.82
Identification of antigens and antibodies specific for Pneumocystis carinii. J Immunol (1988) 1.81
Mechanisms of glucocorticoid action on immune processes. Annu Rev Pharmacol Toxicol (1979) 1.67
Autoantibodies to heparin from patients with antiphospholipid antibody syndrome inhibit formation of antithrombin III-thrombin complexes. Blood (1994) 1.66
Induced sputum to diagnose Pneumocystis carinii pneumonia in immunosuppressed pediatric patients. J Pediatr (1989) 1.63
Coronary endothelial dysfunction after heart transplantation predicts allograft vasculopathy and cardiac death. Circulation (2001) 1.62
Apolipoprotein(a) induces monocyte chemotactic activity in human vascular endothelial cells. Circulation (1997) 1.62
Adult respiratory distress syndrome in patients with severe neutropenia. N Engl J Med (1986) 1.60
Therapy of the hypereosinophilic syndrome. Ann Intern Med (1978) 1.58
Prevalent myocarditis at necropsy in the acquired immunodeficiency syndrome. J Am Coll Cardiol (1988) 1.57
Role of nitric oxide and cGMP in human septic serum-induced depression of cardiac myocyte contractility. Am J Physiol (1999) 1.55
Degradation of human fibrinogen by plasms alpha2-macroglobulin-enzyme complexes. J Clin Invest (1973) 1.54
Validated risk stratification model accurately predicts low risk in patients with unstable angina. J Am Coll Cardiol (2000) 1.54
Heat-induced fragmentation of human alpha 2-macroglobulin. J Biol Chem (1979) 1.53
Complex formation of platelet thrombospondin with plasminogen. Modulation of activation by tissue activator. J Clin Invest (1984) 1.52
A lipid A analog, E5531, blocks the endotoxin response in human volunteers with experimental endotoxemia. Crit Care Med (2000) 1.50
Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol (1987) 1.50
Clinical predictors easily obtained at presentation predict resource utilization in unstable angina. Am Heart J (1998) 1.49
Nitric oxide synthase inhibition increases venular leukocyte rolling and adhesion in septic rats. Crit Care Med (2000) 1.48
Prognostic factors and life expectancy of patients with acquired immunodeficiency syndrome and Pneumocystis carinii pneumonia. Am Rev Respir Dis (1987) 1.47
Human eosinophils. Purification and cytotoxic capability of eosinophils from patients with the hypereosinophilic syndrome. Blood (1978) 1.46
Simultaneous intracoronary ultrasound and Doppler flow studies distinguish flow-mediated from receptor-mediated endothelial responses. Catheter Cardiovasc Interv (1999) 1.46
Comparison of extradural and general anaesthesia on the fibrinolytic response to total knee arthroplasty. Br J Anaesth (1997) 1.45
Proteolytic cleavage and inactivation of alpha 2-plasmin inhibitor and C1 inactivator by human polymorphonuclear leukocyte elastase. J Biol Chem (1982) 1.45
Effect of 100% oxygen administration on infarct size and left ventricular function in a canine model of myocardial infarction and reperfusion. Am Heart J (1995) 1.45
Characterization of de novo folate synthesis in Pneumocystis carinii and Toxoplasma gondii: potential for screening therapeutic agents. J Infect Dis (1989) 1.44
Complex formation of platelet thrombospondin with histidine-rich glycoprotein. J Clin Invest (1984) 1.43
Peak systolic pressure/end-systolic volume ratio, a load-independent measure of ventricular function, is reversibly decreased in human septic shock. Crit Care Med (1994) 1.43
Myocardial dysfunction in septic shock. Crit Care Clin (2000) 1.42
Effects of epinephrine and amrinone on contractility and cyclic adenosine monophosphate generation of tumor necrosis factor alpha-exposed cardiac myocytes. Crit Care Med (1999) 1.42
Does low individual operator coronary interventional procedural volume correlate with worse institutional procedural outcome? J Am Coll Cardiol (1997) 1.41
Nonspecific interstitial pneumonitis: a common cause of pulmonary disease in the acquired immunodeficiency syndrome. Ann Intern Med (1987) 1.41
Characterization of a hyperdynamic murine model of resuscitated sepsis using echocardiography. Am J Respir Crit Care Med (2001) 1.40
Prognostic factors in sepsis: the cold facts. Crit Care Med (1992) 1.40
Validation of computerized three-dimensional reconstruction of intravascular ultrasound: measurements of absolute luminal diameter and cross-sectional area in ex vivo human coronary arteries. J Invasive Cardiol (1992) 1.39
The effects of heterologous platelet transfusion on pulmonary function during ARDS. Chest (1990) 1.39
Discordant epicardial and microvascular endothelial responses in heart transplant recipients early after transplantation. J Heart Lung Transplant (1998) 1.39
Binding of plasminogen to extracellular matrix. J Biol Chem (1986) 1.38
Right ventricular dysfunction and dilatation, similar to left ventricular changes, characterize the cardiac depression of septic shock in humans. Chest (1990) 1.38
Human plasma alpha 2-macroglobulin. An inhibitor of plasma kallikrein. J Exp Med (1970) 1.38
Human alpha2-macroglobulin. Methods Enzymol (1976) 1.38
Cost and appropriateness of radionuclide exercise stress testing by cardiologists and non-cardiologists. Am J Cardiol (1996) 1.38
Disseminated Mycobacterium haemophilum infection in two patients with the acquired immunodeficiency syndrome. Am J Med (1988) 1.36
Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis. J Biol Chem (1991) 1.36
A circulating myocardial depressant substance is associated with cardiac dysfunction and peripheral hypoperfusion (lactic acidemia) in patients with septic shock. Chest (1989) 1.34
Gram-negative bacteremia produces both severe systolic and diastolic cardiac dysfunction in a canine model that simulates human septic shock. J Clin Invest (1986) 1.34
Nonspecific interstitial pneumonitis without evidence of Pneumocystis carinii in asymptomatic patients infected with human immunodeficiency virus (HIV). Ann Intern Med (1988) 1.32
Endocarditis due to resistant viridans streptococci during oral penicillin chemoprophylaxis. N Engl J Med (1979) 1.29
Potent effect of trimetrexate, a lipid-soluble antifolate, on Toxoplasma gondii. J Infect Dis (1987) 1.29
Plasminogen activator inhibitor is associated with the extracellular matrix of cultured bovine smooth muscle cells. J Clin Invest (1987) 1.28
Purification, toxicity, and antiendotoxin activity of polymyxin B nonapeptide. Antimicrob Agents Chemother (1989) 1.25
Septic shock. Hemodynamics and pathogenesis. JAMA (1984) 1.25
Frequency of myocarditis, left ventricular dysfunction and ventricular tachycardia in the acquired immune deficiency syndrome. Am J Cardiol (1988) 1.25
Increased microvascular reactivity and improved mortality in septic mice lacking inducible nitric oxide synthase. Circ Res (2000) 1.24
Comparison of the effector cells in human spontaneous cellular cytotoxicity and antibody-dependent cellular cytotoxicity: differential sensitivity of effector cells to in vivo and in vitro corticosteroids. Scand J Immunol (1978) 1.24
Platelet thrombospondin forms a trimolecular complex with plasminogen and histidine-rich glycoprotein. J Clin Invest (1985) 1.24
Tissue plasminogen activator and urokinase mediate the binding of Glu-plasminogen to plasma fibrin I. Evidence for new binding sites in plasmin-degraded fibrin I. J Biol Chem (1985) 1.23
Potent antipneumocystis and antitoxoplasma activities of piritrexim, a lipid-soluble antifolate. Antimicrob Agents Chemother (1988) 1.19
Dermatologic manifestations of the hypereosinophilic syndrome. Arch Dermatol (1978) 1.19
Myocardial dysfunction in sepsis. Recent insights. Chest (1989) 1.19
Alpha2-plasmin inhibitor and alpha2-macroglobulin-plasmin complexes in plasma. Quantitation by an enzyme-linked differential antibody immunosorbent assay. J Clin Invest (1981) 1.18
Separation of plasma thromboplastin antecedent from kallikrein by the plasma 2 -macroglobulin, kallikrein inhibitor. J Clin Invest (1971) 1.16
Binding of tissue plasminogen activator to cultured human endothelial cells. J Clin Invest (1987) 1.15
Antiphospholipid antibodies accelerate plasma coagulation by inhibiting annexin-V binding to phospholipids: a "lupus procoagulant" phenomenon. Blood (1998) 1.15
The John Charnley Award. Thrombogenesis during total hip arthroplasty. Clin Orthop Relat Res (1995) 1.14
Heart disease and the eosinophil. N Engl J Med (1990) 1.13
Cardiogenic shock. Ann Intern Med (1999) 1.13
Activation of immobilized plasminogen by tissue activator. Multimolecular complex formation. J Biol Chem (1985) 1.12
Bacterial lipopolysaccharides prime human neutrophils for enhanced production of leukotriene B4. J Clin Invest (1989) 1.11
Detection of renal blood flow abnormalities in septic and critically ill patients using a newly designed indwelling thermodilution renal vein catheter. Chest (1990) 1.10
Inhibition of endotoxin-induced priming of human neutrophils by lipid X and 3-Aza-lipid X. J Clin Invest (1987) 1.09
Myocardial dysfunction in septic shock: Part I. Clinical manifestation of cardiovascular dysfunction. J Cardiothorac Vasc Anesth (2001) 1.09
Depressed left ventricular performance. Response to volume infusion in patients with sepsis and septic shock. Chest (1988) 1.09
Norepinephrine alone versus norepinephrine plus low-dose dopamine: enhanced renal blood flow with combination pressor therapy. Crit Care Med (1985) 1.08
Studies on the interaction between collagen and a plasma kallikrein-like activity. Evidence for a surface-active enzyme system. J Clin Invest (1972) 1.08
Electrocardiographic diagnosis of acute myocardial infarction: Current concepts for the clinician. Am Heart J (2001) 1.08
Efficacy of trimetrexate, a potent lipid-soluble antifolate, in the treatment of rodent Pneumocystis carinii pneumonia. Am J Trop Med Hyg (1988) 1.08
Lipoprotein (a) inhibits the generation of transforming growth factor beta: an endogenous inhibitor of smooth muscle cell migration. J Cell Biol (1991) 1.07